Cancer treatment often sounds distant and technical, so stories about it can feel hard to enter. Yet, everyday curiosity ...

Researchers have identified a single protein whose absence can cripple tumors in mice, slowing their growth and in some cases ...

Figure][1] Michael Teitell, MD, PhD Dr. Michael Teitell is the director of the UCLA Health Jonsson Comprehensive Cancer ...

New York, United States, January 7th, 2026, FinanceWireGlobal investment management leader Aurum Capital has announced the ...

True patient-centricity will drive commercial success as CGT moves beyond first-generation therapies. Current timelines in CGT, from diagnosis to treatment, can exceed six months, often compounded by ...

Positive Phase 3 HERIZON-GEA-01 results for Ziihera (zanidatamab-hrii) in first-line HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA) presented at ASCO GI Up to $440.0 million in milestone ...

Ilan’s innovation strategy sets it on a journey with Sheba Medical Center, from the lab bench and clinical research to ...

Detailed price information for Nektar Therapeutics (NKTR-Q) from The Globe and Mail including charting and trades.

Ultimately, Mars will test our biology more than our technology. Every gram of muscle preserved, every synapse protected, every cell repaired will be a triumph of physiology. Space may dismantle the ...

Neoantigens are unique markers that distinguish only cancer cells. By adding B cell reactivity, cancer vaccines can move ...

Noetik CEO and co-founder Ron Alfa, M.D., Ph.D., said the licensing of human foundation models is “a new paradigm in biotech.” With the GSK deal validating the paradigm, in Alfa’s view, Noetik ...

KAIST researchers have developed a way to reprogram immune cells already inside tumors into cancer-killing machines. A drug ...